
Venkata Subba Rao Atluri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6257605/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Recent advances, status, and opportunities of magneto-electric nanocarriers for biomedical applications. Molecular Aspects of Medicine, 2022, 83, 101046.	2.7	11
2	Development of Multifunctional Biopolymeric Auto-Fluorescent Micro- and Nanogels as a Platform for Biomedical Applications. Frontiers in Bioengineering and Biotechnology, 2020, 8, 315.	2.0	26
3	<p>Alzheimer's disease: pathogenesis, diagnostics, and therapeutics</p> . International Journal of Nanomedicine, 2019, Volume 14, 5541-5554.	3.3	646
4	Magnetically guided non-invasive CRISPR-Cas9/gRNA delivery across blood-brain barrier to eradicate latent HIV-1 infection. Scientific Reports, 2019, 9, 3928.	1.6	86
5	Inhibition of Amyloid-Beta Production, Associated Neuroinflammation, and Histone Deacetylase 2-Mediated Epigenetic Modifications Prevent Neuropathology in Alzheimer's Disease in vitro Model. Frontiers in Aging Neuroscience, 2019, 11, 342.	1.7	31
6	Characterization of Nanodiamond-based anti-HIV drug Delivery to the Brain. Scientific Reports, 2018, 8, 1603.	1.6	72
7	Oxidative Stress in HIV Infection and Alcohol Use: Role of Redox Signals in Modulation of Lipid Rafts and ATP-Binding Cassette Transporters. Antioxidants and Redox Signaling, 2018, 28, 324-337.	2.5	19
8	Withaferin A Suppresses Beta Amyloid in APP Expressing Cells: Studies for Tat and Cocaine Associated Neurological Dysfunctions. Frontiers in Aging Neuroscience, 2018, 10, 291.	1.7	19
9	Multifunctional Nanotherapeutics for the Treatment of neuroAIDS in Drug Abusers. Scientific Reports, 2018, 8, 12991.	1.6	26
10	Investigation of ac-magnetic field stimulated nanoelectroporation of magneto-electric nano-drug-carrier inside CNS cells. Scientific Reports, 2017, 7, 45663.	1.6	51
11	Novel nanoformulation to mitigate co-effects of drugs of abuse and HIV-1 infection: towards the treatment of NeuroAIDS. Journal of NeuroVirology, 2017, 23, 603-614.	1.0	20
12	Common gene-network signature of different neurological disorders and their potential implications to neuroAIDS. PLoS ONE, 2017, 12, e0181642.	1.1	11
13	Personalized Therapeutics: First Take Home Messages. , 2017, , 11-23.		0
14	Editorial: HIV and Illicit Drugs of Abuse. Frontiers in Microbiology, 2016, 7, 221.	1.5	10
15	Development of TIMP1 magnetic nanoformulation for regulation of synaptic plasticity in HIV-1 infection. International Journal of Nanomedicine, 2016, Volume 11, 4287-4298.	3.3	20
16	Effect of Cocaine on HIV Infection and Inflammasome Gene Expression Profile in HIV Infected Macrophages. Scientific Reports, 2016, 6, 27864.	1.6	37
17	Coupling of transient near infrared photonic with magnetic nanoparticle for potential dissipation-free biomedical application in brain. Scientific Reports, 2016, 6, 29792.	1.6	15
18	Current status of non-viral gene therapy for CNS disorders. Expert Opinion on Drug Delivery, 2016, 13, 1433-1445.	2.4	73

#	Article	IF	CITATIONS
19	Magnetic nanotherapeutics for dysregulated synaptic plasticity during neuroAIDS and drug abuse. Molecular Brain, 2016, 9, 57.	1.3	18
20	Electrochemical monitoring-on-chip (E-MoC) of HIV-infection in presence of cocaine and therapeutics. Biosensors and Bioelectronics, 2016, 86, 426-431.	5.3	27
21	HIV and Cocaine Impact Clial Metabolism: Energy Sensor AMP-activated protein kinase Role in Mitochondrial Biogenesis and Epigenetic Remodeling. Scientific Reports, 2016, 6, 31784.	1.6	26
22	Magnetically guided central nervous system delivery and toxicity evaluation of magneto-electric nanocarriers. Scientific Reports, 2016, 6, 25309.	1.6	92
23	Profile of Class I Histone Deacetylases (HDAC) by Human Dendritic Cells after Alcohol Consumption and In Vitro Alcohol Treatment and Their Implication in Oxidative Stress: Role of HDAC Inhibitors Trichostatin A and Mocetinostat. PLoS ONE, 2016, 11, e0156421.	1.1	11
24	HIV Subtypes B and C gp120 and Methamphetamine Interaction: Dopaminergic System Implicates Differential Neuronal Toxicity. Scientific Reports, 2015, 5, 11130.	1.6	15
25	Therapeutical Neurotargeting via Magnetic Nanocarrier: Implications to Opiate-Induced Neuropathogenesis and NeuroAIDS. Journal of Biomedical Nanotechnology, 2015, 11, 1722-1733.	0.5	30
26	Investigation of Neuropathogenesis in HIV-1 Clade B and C Infection Associated with IL-33 and ST2 Regulation. ACS Chemical Neuroscience, 2015, 6, 1600-1612.	1.7	26
27	Sterile alpha motif and histidine/aspartic acid domain-containing protein 1 (SAMHD1)-facilitated HIV restriction in astrocytes is regulated by miRNA-181a. Journal of Neuroinflammation, 2015, 12, 66.	3.1	30
28	Preparation and characterization of anti-HIV nanodrug targeted to microfold cell of gut-associated lymphoid tissue. International Journal of Nanomedicine, 2015, 10, 5819.	3.3	25
29	HIV-1 gp120 and morphine induced oxidative stress: role in cell cycle regulation. Frontiers in Microbiology, 2015, 6, 614.	1.5	32
30	DJ1 expression downregulates in neuroblastoma cells (SK-N-MC) chronically exposed to HIV-1 and cocaine. Frontiers in Microbiology, 2015, 6, 749.	1.5	6
31	Downregulation of host tryptophan–aspartate containing coat (TACO) gene restricts the entry and survival of Leishmania donovani in human macrophage model. Frontiers in Microbiology, 2015, 6, 946.	1.5	8
32	Alcohol and Cannabinoids Differentially Affect HIV Infection and Function of Human Monocyte-Derived Dendritic Cells (MDDC). Frontiers in Microbiology, 2015, 6, 1452.	1.5	13
33	Effect of human immunodeficiency virus on blood-brain barrier integrity and function: an update. Frontiers in Cellular Neuroscience, 2015, 9, 212.	1.8	98
34	Sustained-release nanoART formulation for the treatment of neuroAIDS. International Journal of Nanomedicine, 2015, 10, 1077.	3.3	94
35	Synaptic Plasticity and Neurological Disorders in Neurotropic Viral Infections. Neural Plasticity, 2015, 2015, 1-14.	1.0	15
36	Cell cycle checkpoints and pathogenesis of HIV-1 infection: a brief overview. Journal of Basic and Clinical Physiology and Pharmacology, 2015, 26, 1-11.	0.7	8

#	Article	IF	CITATIONS
37	Drugs of Abuse in HIV infection and neurotoxicity. Frontiers in Microbiology, 2015, 6, 217.	1.5	16
38	Electrochemical sensing method for point-of-care cortisol detection in human immunodeficiency virus-infected patients. International Journal of Nanomedicine, 2015, 10, 677.	3.3	49
39	Natural Products as Anti-HIV Agents and Role in HIV-Associated Neurocognitive Disorders (HAND): A Brief Overview. Frontiers in Microbiology, 2015, 6, 1444.	1.5	69
40	HIV-1 Subtypes B and C Tat Differentially Impact Synaptic Plasticity Expression and Implicates HIV-Associated Neurocognitive Disorders§. Current HIV Research, 2015, 12, 397-405.	0.2	23
41	Pediatric Neurocysticercosis: Usefulness of Antibody Response in Cysticidal Treatment Follow-Up. BioMed Research International, 2014, 2014, 1-8.	0.9	6
42	Immunoneuropathogenesis of HIV-1 clades B and C: Role of redox expression and thiol modification. Free Radical Biology and Medicine, 2014, 69, 136-144.	1.3	19
43	Enhanced blood–brain barrier transmigration using a novel transferrin embedded fluorescent magneto-liposome nanoformulation. Nanotechnology, 2014, 25, 055101.	1.3	102
44	Vorinostat positively regulates synaptic plasticity genes expression and spine density in HIV infected neurons: role of nicotine in progression of HIV-associated neurocognitive disorder. Molecular Brain, 2014, 7, 37.	1.3	35
45	β-Amyloid1-42, HIV-1Ba-L (Clade B) Infection and Drugs of Abuse Induced Degeneration in Human Neuronal Cells and Protective Effects of Ashwagandha (Withania somnifera) and Its Constituent Withanolide A. PLoS ONE, 2014, 9, e112818.	1.1	31
46	Magneto-electric Nanoparticles to Enable Field-controlled High-Specificity Drug Delivery to Eradicate Ovarian Cancer Cells. Scientific Reports, 2013, 3, 2953.	1.6	123
47	Human Synaptic Plasticity Gene Expression Profile and Dendritic Spine Density Changes in HIV-Infected Human CNS Cells: Role in HIV-Associated Neurocognitive Disorders (HAND). PLoS ONE, 2013, 8, e61399.	1.1	57
48	Targeted Brain Derived Neurotropic Factors (BDNF) Delivery across the Blood-Brain Barrier for Neuro-Protection Using Magnetic Nano Carriers: An In-Vitro Study. PLoS ONE, 2013, 8, e62241.	1.1	109
49	Ashwagandha (Withania somnifera) Reverses β-Amyloid1-42 Induced Toxicity in Human Neuronal Cells: Implications in HIV-Associated Neurocognitive Disorders (HAND). PLoS ONE, 2013, 8, e77624.	1.1	101
50	Inhibition of Nuclear Factor Erythroid 2-Related Factor 2 Exacerbates HIV-1 gp120-Induced Oxidative and Inflammatory Response: Role in HIV Associated Neurocognitive Disorder. Neurochemical Research, 2012, 37, 1697-1706.	1.6	25
51	2D-PAGE analysis of Taenia solium metacestode 10–30kDa antigens for the serodiagnosis of neurocysticercosis in children. Acta Tropica, 2011, 118, 165-169.	0.9	7
52	The role of alanine 163 in solute permeability of Leishmania major aquaglyceroporin LmAQP1. Molecular and Biochemical Parasitology, 2011, 175, 83-90.	0.5	26
53	Two-dimensional gel electrophoresis analysis of T. solium cysticerci lower molecular mass (10–30kDa) antigens for the serodiagnosis of neurocysticercosis in children. International Journal of Infectious Diseases, 2010, 14, e289-e290.	1.5	0
54	Evaluation of excretory secretory and 10–30ÂkDa antigens of <i>Taenia solium Cysticerci</i> by EITB assay for the diagnosis of neurocysticercosis. Parasite Immunology, 2009, 31, 151-155.	0.7	18

#	Article	IF	CITATIONS
55	Neurocysticercosis immunodiagnosis using Taenia solium cysticerci crude soluble extract, excretory secretory and lower molecular mass antigens in serum and urine samples of Indian children. Acta Tropica, 2009, 110, 22-27.	0.9	21